What is RenovoRx Inc Annual Net Profit?

RenovoRx Inc Annual Net Profit rose 13.86% in the last year to $8.81 M. Its sector's average net profit growth for the last fiscal year was -30.36%.

What is RenovoRx Inc Price to Earning Ratio?

RenovoRx Inc Price to Earning Ratio is -4.23, which is negative.

What is RenovoRx Inc Stock Price?

RenovoRx Inc Stock Price fell 12.82% and underperformed its sector by 20.15% in the past year.

What is RenovoRx Inc Quarterly Net profit?

RenovoRx Inc Quarterly Net profit rose 10.81% YoY to $2.88 M. Its sector's average net profit growth YoY for the quarter was -48.37%.

What is RenovoRx Inc Mutual Fund Holding?

RenovoRx Inc Mutual Fund Holding increased by 2.54% in the last quarter to 4.75.

What is RenovoRx Inc Institutional Holding?

RenovoRx Inc Institutional Holding remained the same in the last quarter at 12.47%.

How is the RenovoRx Inc today?

The RenovoRx Inc today is trading in the down by -0.97% at 1.02.

How has RenovoRx Inc performed historically?

The RenovoRx Inc is currently trading down -0.97% on an intraday basis in the past week the index rose 32.47%. The index has been down -32.00% in the past quarter and fell -12.82% in the past year. You can view this in the overview section.

RenovoRx Inc XNAS: RNXT

RenovoRx Inc Live Share Price Today, Share Analysis and Chart

Name: RenovoRx Inc: Is Infosys Ltd. worth buying?
Item: RenovoRx Inc
Rating: 1.15425
Author: Trendlyne DVM scores

Download real time

1.02 -0.01 (-0.97%)

39.64% Fall from 52W High

109.2K XNAS Volume

XNAS 17 Apr, 2025 5:30 PM (EDT)

RenovoRx Inc Key Metrics

My Metrics

Default

Market Capitalization Below industry Median Unavailable in chosen country	37.3
PE TTM Negative PE TTM Unavailable in chosen country	-4.2
PEG TTM Negative PEG TTM Unavailable in chosen country	-0.3
Price to Book High in industry Unavailable in chosen country	5.3
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	12.5
Net Profit Qtr Growth YoY % Below industry Median Unavailable in chosen country	10.8
Net Profit TTM Growth % Below industry Median Unavailable in chosen country	13.9
Operating Profit Margin TTM % Negative Operating Profit Margin TTM % Unavailable in chosen country	-25,511.6
Piotroski Score Low in industry Unavailable in chosen country	1
Rel Perf vs Sector quarter% Unavailable in chosen country	-31

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

4.0 / 100

Technically Neutral

42.2 / 100

1Yr Price target upside is 378%

4 analysts

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

RenovoRx Inc Stock Price Analysis

Day Price Range -1.0% 1 Day return Unavailable in chosen country	1 (LTP) 11 LowHigh
Week Price Range 32.5% 1 Week return Unavailable in chosen country	1 (LTP) 0.81 LowHigh
Month Price Range 3.0% 1 Month return Unavailable in chosen country	1 (LTP) 0.81.1 LowHigh
52 Week Price Range -12.8% 1 Year return Unavailable in chosen country	1 (LTP) 0.81.7 LowHigh

View full Share Price History

RenovoRx Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

EPS forecast

QUARTER
ANNUAL

Current EPS

-0.4

Avg. Estimate

-0.3

Low Estimate

-0.3

High Estimate

-0.3

Current EPS

Avg. Estimate

Hit

EPS is expected to grow by 25.0% in FY25

Consensus Recommendation

4 ANALYST Recommendations

BUY

The consensus recommendation from 4 analysts for RenovoRx Inc is BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

RenovoRx Inc Stock Analysis

RenovoRx Inc stock analysis with key metrics, changes, and trends.

RenovoRx Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Net Profit	$8.81 M	13.86%	positive	Annual Net Profit rose 13.86% in the last year to $8.81 M. Its sector's average net profit growth for the last fiscal year was -30.36%.
Price to Earning Ratio	-4.23	-	negative	Price to Earning Ratio is -4.23, which is negative.
Stock Price	$1.02	-12.82%	negative	Stock Price fell 12.82% and underperformed its sector by 20.15% in the past year.
Quarterly Net profit	$2.88 M	10.81%	positive	Quarterly Net profit rose 10.81% YoY to $2.88 M. Its sector's average net profit growth YoY for the quarter was -48.37%.
Mutual Fund Holding	4.75 %	2.54%	positive	Mutual Fund Holding increased by 2.54% in the last quarter to 4.75.
Institutional Holding	12.47 %	0%	neutral	Institutional Holding remained the same in the last quarter at 12.47%.

VIEW LESS

Loading data..

RenovoRx Inc - Company Profile

What does RenovoRx Inc do?

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Gross Remuneration

2024

Gross Remuneration

Year

RenovoRx Inc Live Share Price Today, Share Analysis and Chart

39.64% Fall from 52W High

RenovoRx Inc Key Metrics

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

RenovoRx Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

RenovoRx Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

EPS forecast

EPS is expected to grow by 25.0% in FY25

Consensus Recommendation

The consensus recommendation from 4 analysts for RenovoRx Inc is BUY

RenovoRx Inc Stock Analysis

RenovoRx Inc stock analysis with key metrics, changes, and trends.

Annual Net Profit rose 13.86% in the last year to $8.81 M. Its sector's average net profit growth for the last fiscal year was -30.36%.

Price to Earning Ratio is -4.23, which is negative.

Stock Price fell 12.82% and underperformed its sector by 20.15% in the past year.

Quarterly Net profit rose 10.81% YoY to $2.88 M. Its sector's average net profit growth YoY for the quarter was -48.37%.

Mutual Fund Holding increased by 2.54% in the last quarter to 4.75.

Institutional Holding remained the same in the last quarter at 12.47%.

RenovoRx Inc - Company Profile

What does RenovoRx Inc do?

RenovoRx Inc Management structure

Mr. James M. Ahlers

Principal Accounting Officer, Chief Financial Officer, Secretary and Treasurer

Ms. Angela Gill Nelms

Chief Operating Officer

Mr. Ronald B. Kocak

Vice President, Controller and Principal Accounting Officer

Ms. Leesa Gentry

Senior Vice President, Clinical Operations

Mr. Shaun R. Bagai

Chief Executive Officer and Director

Dr. Ramtin Agah, M.D.

Chief Medical Officer and Chairman of the Board

RenovoRx Inc Board of directors

Dr. Una S. Ryan,PhD

Independent Director

Dr. Laurence J. Marton, M.D.

Independent Director

Dr. Robert J. Spiegel, F.A.C.P.,M.D.

Independent Director

Mr. Shaun R. Bagai

Chief Executive Officer and Director

Dr. Ramtin Agah, M.D.

Chief Medical Officer and Chairman of the Board

Ms. Kirsten Angela Macfarlane

Independent Director

RenovoRx Inc FAQ

How is RenovoRx Inc today?

RenovoRx Inc today is trading in the red, and is down by -0.97% at 1.02.

How has RenovoRx Inc performed historically?

RenovoRx Inc is currently trading down -0.97% on an intraday basis. In the past week the stock rose 32.47%. stock has been down -32.00% in the past quarter and fell -12.82% in the past year. You can view this in the overview section.